Cost-effectiveness of combinatorial pharmacogenomic testing for treatment-resistant major depressive disorder patients

The American journal of managed care

Volumn 21, Issue 6, 2015, Pages e357-e365

  Hornberger, John ^a   Li, Qianyi ^b   Quinn, Bruce ^b  

^a Cedar Associates LLC   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT;

COST BENEFIT ANALYSIS; DEPRESSIVE DISORDER, MAJOR; DRUG RESISTANCE; ECONOMICS; GENETICS; HUMAN; META ANALYSIS; PHARMACOGENETIC TESTING; QUALITY ADJUSTED LIFE YEAR;

ANTIDEPRESSIVE AGENTS; COST-BENEFIT ANALYSIS; DEPRESSIVE DISORDER, MAJOR; DRUG RESISTANCE; HUMANS; PHARMACOGENOMIC TESTING; QUALITY-ADJUSTED LIFE YEARS;

EID: 85016925201     PISSN: None     EISSN: 19362692     Source Type: Journal    
DOI: None     Document Type: Article

References (0)